Ingenuity Technology Licensed by Schering-Plough Research Institute (SPRI)
NEW Ingenuity Pathways Analysis 3.0 Deployed to SPRI Researchers
Ingenuity announced that Schering-Plough Research Institute, the global pharmaceutical research arm of Schering-Plough Corporation has licensed both Ingenuity Pathways Analysis and the Ingenuity Pathways Analysis Integration Module (IPA-IM).
Ingenuity Pathways Analysis 3.0 (IPA), released last month, enables biologists and bioinformaticians to model, analyze, and understand the complex biological systems at the core of all life science research. IPA leverages the world largest and highest quality knowledge base of biological networks and powerful algorithms, along with an exceptionally easy-to-use software interface, to provide researchers with the insights and confidence needed to make better and faster decisions at every step of their research.
With access to the new release of Ingenuity Pathways Analysis 3.0, scientists will now be able to integrate their own biological relationships with Ingenuity pathways to create custom networks for particular targets, biomarkers, disease areas, and processes and enable powerful computation and functional analysis. Researchers will also benefit from Ingenuity Pathways Analysis 3.0's vastly expanded search capabilities and a doubling of the gene and disease content.
Other news from the department business & finance
